DOCKET NO.: ISIS-5582
Application No.: 10/510,667
Office Action mailed: November 15, 2006

PATENT

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) An oligomeric compound having the formula:



wherein:

each Bx is, independently, a heterocyclic base moiety;

~~T_1 and~~ T_2 ~~are each independently,~~ is hydroxyl, a protected hydroxyl, an ~~oligonucleotide,~~ oligonucleotide or an ~~oligonucleoside~~ oligonucleoside; ~~or a modified phosphate group having the formula~~:

T_1 is a modified phosphate having the formula:



wherein

one of Q_1 and Q_2 is S and the other of Q_1 and Q_2 is O;

Q_3 is OH or ~~CH_3~~; CH_3 when Q_2 is S and CH_3 when Q_2 is O;

R_1, R_3 and each R_2 ~~is,~~ are, independently, hydrogen, hydroxyl, a sugar substituent group, a protected sugar substituent group or said modified phosphate group;

each X_1 and X_2 is, independently, O or S wherein at least one X_1 is S; and

n is from 3 to 48~~; and~~

~~wherein at least one of T_1 or T_2 is said modified phosphate group~~.

2. (original) The oligomeric compound of claim 1 wherein Q_1 is S.

3. (original) The oligomeric compound of claim 1 wherein Q_2 is S.

4. (original) The oligomeric compound of claim 1 wherein Q_3 is CH_3.

5-10. (canceled)

11. (original) The oligomeric compound of claim 1 wherein R_1, R_3 and each R_2 is hydrogen.

12. (original) The oligomeric compound of claim 1 wherein R_1, R_3 and each R_2 is hydroxyl.

13. (currently amended) The oligomeric compound of claim 1 wherein R_1, R_3 and each R_2 ~~is,~~ are, independently, hydrogen, hydroxyl, a sugar substituent group or a protected sugar substituent group.

14. (original) The oligomeric compound of claim 1 wherein at least one of R_1, R_2 or R_3 is an optionally protected sugar substituent group.

15. (original) The oligomeric compound of claim 1 wherein each X_2 is S.

16. (original) The oligomeric compound of claim 1 wherein each heterocyclic base moiety is, independently, adenine, cytosine, 5-methylcytosine, thymine, uracil, guanine or 2-aminoadenine.

17. (original) The oligomeric compound of claim 1 wherein n is from about 8 to about 30.

18. (original) The oligomeric compound of claim 1 wherein n is from about 15 to 25.

PAGE 4/7 * RCVD AT 2/9/2007 2:27:58 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-2/0 * DNIS:2738300 * CSID:7606033820 * DURATION (mm-ss):02-12

19. (withdrawn) A method of treating an organism having a disease characterized by the undesired production of a protein comprising contacting the organism with an oligomeric compound of claim 1.

20. (currently amended) A ~~pharmaceutical~~ composition comprising:

a pharmaceutically effective amount of an oligomeric compound of claim 1; and

a pharmaceutically acceptable diluent or carrier.

21. (withdrawn) A method of modifying *in vitro* a nucleic acid, comprising contacting a test solution containing RNase H and said nucleic acid with an oligomeric compound of claim 1.

22. (withdrawn) A method of concurrently enhancing hybridization and RNase H activation in a organism comprising contacting the organism with an oligomeric compound of claim 1.

23. (withdrawn) A method comprising contacting a cell with an oligomeric compound of claim 1.

24-41. (canceled)

PAGE 5/7 * RCVD AT 2/9/2007 2:27:58 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-2/0 * DNIS:2738300 * CSID:7606033820 * DURATION (mm-ss):02-12